Proscia

Name: Proscia
Brand: Proscia

Pathology AI. #1 Best in KLAS. Enterprise-grade intelligence for the decisions that matter most.

Est 2016|Valuation $243M|Raised $129.3M|1 Ref Customers

LinkedIn 21K|Web traffic 20K|FTEs 126|HQ Philadelphia, Pennsylvania, US

01Competitive Landscape

Narrative analysis

1) Enterprise imaging and interoperability - Proscia emphasizes support for multiple scanner models and standards-based interoperability testing. Sectra emphasizes integration of pathology into enterprise image management for cross-modality workflows. 2) Primary diagnosis credibility - Proscia: FDA 510(k) clearance exists for Concentriq AP-Dx for specified indications and conditions of use. Buyers should review clearance details and intended use statements. - Philips and other established vendors also hold regulatory clearances for their solutions; specific pathways and cleared configurations vary by vendor. 3) Market adoption signals - Independent market research and analyst reports historically show established vendors such as Leica and Philips with significant provider consideration; Proscia is positioned among vendors used by early adopters and organizations pursuing AI-enabled workflows. Buyers should consult independent analyst reports and reference customers for current adoption patterns. 4) When competitors may be chosen instead - Buyers seeking a single accountable vendor for scanner, IMS, and validated end-to-end workflow may prefer an integrated vendor. - Organizations prioritizing enterprise imaging consolidation and radiology-pathology collaboration may prefer offerings that emphasize cross-modality workflows and enterprise image management. - Vendors with explicit third-party certifications (e.g., ISO/IEC 27001 stated by some competitors) may be preferred where public certification evidence is a procurement requirement.

	Proscia Concentriq	Philips IntelliSite Pathology Solution	Sectra Digital Pathology Solution
Pricing	Not publicly listed (enterprise quote required)	Not publicly listed (enterprise quote required)	Not publicly listed (enterprise quote required)
Typical fit	Organizations seeking a single image management platform that supports multiple scanner models and AI integration across research and diagnostics	Organizations seeking an integrated scanner+software ecosystem with validated workflows	Enterprises seeking pathology within a broader enterprise imaging strategy and cross-modality workflow orchestration
Noted strengths	FDA-cleared option for primary diagnosis under specified conditions; emphasis on support for multiple scanners and AI integration	Long market presence in primary diagnosis deployments; integrated hardware/software ecosystem	Enterprise imaging integration and workflow orchestration; positioning for cross-modality use cases
Noted weaknesses	Limited public disclosure on pricing and some security attestations in public materials; fewer mainstream product-review signals discovered in this research	Potential for increased vendor lock-in within an end-to-end ecosystem	May be better suited to organizations already invested in the vendor's enterprise imaging stack

01Competitive Landscape

Narrative analysis

Enterprise imaging and interoperability

Proscia emphasizes support for multiple scanner models and standards-based interoperability testing. Sectra emphasizes integration of pathology into enterprise image management for cross-modality workflows.

Primary diagnosis credibility

Proscia: FDA 510(k) clearance exists for Concentriq AP-Dx for specified indications and conditions of use. Buyers should review clearance details and intended use statements.
Philips and other established vendors also hold regulatory clearances for their solutions; specific pathways and cleared configurations vary by vendor.

Market adoption signals

Independent market research and analyst reports historically show established vendors such as Leica and Philips with significant provider consideration; Proscia is positioned among vendors used by early adopters and organizations pursuing AI-enabled workflows. Buyers should consult independent analyst reports and reference customers for current adoption patterns.

When competitors may be chosen instead

Buyers seeking a single accountable vendor for scanner, IMS, and validated end-to-end workflow may prefer an integrated vendor.
Organizations prioritizing enterprise imaging consolidation and radiology-pathology collaboration may prefer offerings that emphasize cross-modality workflows and enterprise image management.
Vendors with explicit third-party certifications (e.g., ISO/IEC 27001 stated by some competitors) may be preferred where public certification evidence is a procurement requirement.

	Proscia Concentriq	Philips IntelliSite Pathology Solution	Sectra Digital Pathology Solution
Pricing	Not publicly listed (enterprise quote required)	Not publicly listed (enterprise quote required)	Not publicly listed (enterprise quote required)
Typical fit	Organizations seeking a single image management platform that supports multiple scanner models and AI integration across research and diagnostics	Organizations seeking an integrated scanner+software ecosystem with validated workflows	Enterprises seeking pathology within a broader enterprise imaging strategy and cross-modality workflow orchestration
Noted strengths	FDA-cleared option for primary diagnosis under specified conditions; emphasis on support for multiple scanners and AI integration	Long market presence in primary diagnosis deployments; integrated hardware/software ecosystem	Enterprise imaging integration and workflow orchestration; positioning for cross-modality use cases
Noted weaknesses	Limited public disclosure on pricing and some security attestations in public materials; fewer mainstream product-review signals discovered in this research	Potential for increased vendor lock-in within an end-to-end ecosystem	May be better suited to organizations already invested in the vendor's enterprise imaging stack

Proscia

01Competitive Landscape

Narrative analysis

02Market Map

01Competitive Landscape

Narrative analysis

02Market Map